Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan.

ABSTRACT:

Backgrounds

Pancreatic cancer is a highly aggressive disease with limited treatment options. The combination of tegafur, gimeracil, and oteracil (S-1) has emerged as a promising treatment approach in Japan. However, the economic implications of S-1 compared to other chemotherapy regimens have not been fully explored.

Methods

This cost-effectiveness analysis study evaluated the economic position of S-1 relative to fluorouracil+leucovorin+irinotecan+oxaliplatin (FFX), gemcitabine+Nab-paclitaxel (GnP), and gemcitabine (GEM) for the treatment of distant metastatic pancreatic cancer in Japan. Incremental cost-effectiveness ratios were calculated using quality-adjusted life years (QALYs) as the measure of effectiveness.

Results

S-1 demonstrated the lowest incremental cost-e

SUBMITTER: Sasahara Y 

PROVIDER: S-EPMC12434479 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature